Global Cord Blood Corp
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation… Read more
Global Cord Blood Corp (CORBF) - Net Assets
Latest net assets as of June 2022: $770.59 Million USD
Based on the latest financial reports, Global Cord Blood Corp (CORBF) has net assets worth $770.59 Million USD as of June 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.35 Billion) and total liabilities ($575.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $770.59 Million |
| % of Total Assets | 57.24% |
| Annual Growth Rate | 23.43% |
| 5-Year Change | 56.63% |
| 10-Year Change | 293.49% |
| Growth Volatility | 119.4 |
Global Cord Blood Corp - Net Assets Trend (2007–2022)
This chart illustrates how Global Cord Blood Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Global Cord Blood Corp (2007–2022)
The table below shows the annual net assets of Global Cord Blood Corp from 2007 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-03-31 | $4.88 Billion | +11.31% |
| 2021-03-31 | $4.39 Billion | +12.86% |
| 2020-03-31 | $3.89 Billion | +13.61% |
| 2019-03-31 | $3.42 Billion | +9.75% |
| 2018-03-31 | $3.12 Billion | +69.26% |
| 2017-03-31 | $1.84 Billion | +7.54% |
| 2016-03-31 | $1.71 Billion | +11.03% |
| 2015-03-31 | $1.54 Billion | +7.17% |
| 2014-03-31 | $1.44 Billion | +15.99% |
| 2013-03-31 | $1.24 Billion | +0.47% |
| 2012-03-31 | $1.24 Billion | +13.01% |
| 2011-03-31 | $1.09 Billion | +33.40% |
| 2010-03-31 | $819.61 Million | +484.26% |
| 2009-03-31 | $140.28 Million | -28.95% |
| 2008-03-31 | $197.44 Million | -4.93% |
| 2007-03-31 | $207.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Global Cord Blood Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15946458.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.89 Billion | 59.17% |
| Common Stock | $83.00K | 0.00% |
| Other Comprehensive Income | $-106.79 Million | -2.19% |
| Other Components | $2.10 Billion | 43.01% |
| Total Equity | $4.88 Billion | 100.00% |
Global Cord Blood Corp Competitors by Market Cap
The table below lists competitors of Global Cord Blood Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stellar V Capital Corp. Unit
NASDAQ:SVCCU
|
$134.03 Million |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
$134.04 Million |
|
Kitex Garments Limited
NSE:KITEX
|
$134.11 Million |
|
Saha Pathanapibul Public Company Limited
BK:SPC
|
$134.12 Million |
|
Hubtown Limited
NSE:HUBTOWN
|
$134.00 Million |
|
Guangxi Guidong Eletric Power Co Ltd
SHG:600310
|
$134.00 Million |
|
Far East Orchard Ltd
F:O5P
|
$133.98 Million |
|
Hangzhou Huasu Technology Co. Ltd. A
SHE:301157
|
$133.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Global Cord Blood Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 4,381,858,000 to 4,879,316,000, a change of 497,458,000 (11.4%).
- Net income of 501,065,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 3,607,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $501.06 Million | +10.27% |
| Other Comprehensive Income | $-3.61 Million | -0.07% |
| Total Change | $- | 11.35% |
Book Value vs Market Value Analysis
This analysis compares Global Cord Blood Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-03-31 | $139.60 | $1.15 | x |
| 2008-03-31 | $28.21 | $1.15 | x |
| 2009-03-31 | $20.05 | $1.15 | x |
| 2010-03-31 | $10.86 | $1.15 | x |
| 2011-03-31 | $15.30 | $1.15 | x |
| 2012-03-31 | $16.31 | $1.15 | x |
| 2013-03-31 | $16.39 | $1.15 | x |
| 2014-03-31 | $17.41 | $1.15 | x |
| 2015-03-31 | $19.49 | $1.15 | x |
| 2016-03-31 | $23.49 | $1.15 | x |
| 2017-03-31 | $23.16 | $1.15 | x |
| 2018-03-31 | $26.13 | $1.15 | x |
| 2019-03-31 | $28.17 | $1.15 | x |
| 2020-03-31 | $31.94 | $1.15 | x |
| 2021-03-31 | $36.05 | $1.15 | x |
| 2022-03-31 | $40.14 | $1.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Global Cord Blood Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.27%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 40.30%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.75x
- Recent ROE (10.27%) is above the historical average (6.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.01% | 0.00% | 0.00x | 1.27x | $-20.75 Million |
| 2008 | 1.45% | 20.85% | 0.06x | 1.26x | $-16.87 Million |
| 2009 | -5.62% | -27.66% | 0.14x | 1.40x | $-21.91 Million |
| 2010 | 6.08% | 18.80% | 0.25x | 1.29x | $-31.71 Million |
| 2011 | 8.56% | 27.01% | 0.22x | 1.46x | $-15.38 Million |
| 2012 | 10.97% | 34.69% | 0.21x | 1.52x | $11.71 Million |
| 2013 | 9.09% | 21.37% | 0.18x | 2.41x | $-11.27 Million |
| 2014 | 9.19% | 23.03% | 0.16x | 2.53x | $-11.60 Million |
| 2015 | 6.98% | 16.89% | 0.15x | 2.68x | $-46.48 Million |
| 2016 | 5.32% | 13.72% | 0.14x | 2.74x | $-79.96 Million |
| 2017 | 6.87% | 16.60% | 0.15x | 2.82x | $-57.60 Million |
| 2018 | 7.62% | 25.31% | 0.16x | 1.88x | $-74.24 Million |
| 2019 | 8.52% | 29.50% | 0.15x | 1.92x | $-50.61 Million |
| 2020 | 12.13% | 38.54% | 0.17x | 1.86x | $82.50 Million |
| 2021 | 11.60% | 43.83% | 0.15x | 1.80x | $70.06 Million |
| 2022 | 10.27% | 40.30% | 0.15x | 1.75x | $13.13 Million |
Industry Comparison
This section compares Global Cord Blood Corp's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Global Cord Blood Corp (CORBF) | $770.59 Million | 0.01% | 0.75x | $134.00 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |